A5069208658- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Immunodeficiency and Autoimmune Disorders
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Monoclonal and Polyclonal Antibodies Research
- Protein Degradation and Inhibitors
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- Neutropenia and Cancer Infections
- Retinoids in leukemia and cellular processes
- Cancer-related molecular mechanisms research
- Mycobacterium research and diagnosis
- Hematopoietic Stem Cell Transplantation
- MicroRNA in disease regulation
- Epigenetics and DNA Methylation
- Glycosylation and Glycoproteins Research
- Cancer therapeutics and mechanisms
- RNA Interference and Gene Delivery
- Phagocytosis and Immune Regulation
- CAR-T cell therapy research
Northwell Health
2016-2025
North Shore University Hospital
2010-2025
Long Island Jewish Medical Center
2003-2025
Feinstein Institute for Medical Research
2015-2025
Hofstra University
2016-2025
North Shore Diabetes and Endocrine Associates
2024
Donald & Barbara Zucker School of Medicine at Hofstra/Northwell
2018-2023
Institute for Molecular Medicine
2021
Cornell University
1981-2018
Moffitt Cancer Center
2007-2018
Fludarabine is an effective treatment for chronic lymphocytic leukemia that does not respond to initial with chlorambucil. We compared the efficacy of fludarabine chlorambucil in primary leukemia.
Purpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers synergistic 5:1 drug ratio into leukemia cells to greater extent than normal bone marrow cells. Prior clinical studies demonstrated sustained exposure in vivo prolonged survival versus standard-of-care plus chemotherapy (7+3 regimen) older patients with newly diagnosed secondary acute myeloid (sAML). Patients Methods In this open-label, randomized, phase III trial, 309 age 60 75 years...
Purpose To analyze the frequency and associations with prognostic markers outcome of mutations in IDH genes encoding isocitrate dehydrogenases adult de novo cytogenetically normal acute myeloid leukemia (CN-AML). Patients Methods Diagnostic bone marrow or blood samples from 358 patients were analyzed for IDH1 IDH2 by DNA polymerase chain reaction amplification/sequencing. FLT3, NPM1, CEBPA, WT1, MLL mutational analyses gene- microRNA-expression profiling performed centrally. Results found...
To analyze the prognostic impact of mutated KIT (mutKIT) in core-binding factor acute myeloid leukemia (AML) with inv(16)(p13q22) and t(8;21)(q22;q22).Sixty-one adults inv(16) 49 t(8;21), assigned to postremission therapy repetitive cycles higher dose cytarabine were analyzed for mutKIT exon 17 (mutKIT17) 8 (mutKIT8) by denaturing high-performance liquid chromatography direct sequencing at diagnosis. The median follow-up was 5.3 years.Among patients inv(16), 29.5% had (16% mutKIT17 13% sole...
Due to its relatively slow clinical progression, B cell chronic lymphocytic leukemia (B-CLL) is classically described as a disease of accumulation rather than proliferation. However, evidence for various forms clonal evolution suggests that B-CLL clones may be more dynamic previously assumed. We used nonradioactive, stable isotopic labeling method measure kinetics in vivo. Nineteen patients drank an aliquot deuterated water (2H2O) daily 84 days, and 2H incorporation into the deoxyribose...
A microRNA signature in molecularly defined
Previous studies suggest that the diversity of expressed variable (V) region repertoire immunoglobulin (Ig)H chain B-CLL cells is restricted. Although limited examples marked constraint in primary structure H and L V regions exist, possibility this level restriction a general principle disease has not been accepted. This report describes five sets patients, mostly with unmutated or minimally mutated IgV genes, strikingly similar B cell antigen receptors (BCRs) arising from use common gene...
To evaluate the prognostic significance of international European LeukemiaNet (ELN) guidelines for reporting genetic alterations in acute myeloid leukemia (AML).We analyzed 1,550 adults with primary AML, treated on Cancer and Leukemia Group B first-line trials, who had pretreatment cytogenetics and, cytogenetically normal patients, mutational status NPM1, CEBPA, FLT3 available. We compared complete remission (CR) rates, disease-free survival (DFS), overall (OS) among patients classified into...
Purpose Because both t(8;21) and inv(16) disrupt core binding factor (CBF) in acute myeloid leukemia (AML) confer relatively favorable prognoses, these cytogenetic groups are often treated similarly. Recent studies, however, have shown different gene profiling for the two groups, underscoring potential biologic differences. Therefore, we sought to determine whether should also be considered separate entities from a clinical standpoint. Patients Methods We analyzed 144 consecutive adults with...
To analyze the prognostic significance of NPM1 mutations, and associated gene- microRNA-expression signatures in older patients with de novo, cytogenetically normal acute myeloid leukemia (CN-AML) treated intensive chemotherapy.One hundred forty-eight adults age >or= 60 years novo CN-AML, enrolled onto Cancer Leukemia Group B protocols 9720 10201, were studied at diagnosis for NPM1, FLT3, CEBPA, WT1 profiles.Patients mutations (56%) had higher complete remission (CR) rates (84% v 48%; P <...
Purpose To determine the frequency of TET2 mutations, their associations with clinical and molecular characteristics outcome, associated gene- microRNA-expression signatures in patients primary cytogenetically normal acute myeloid leukemia (CN-AML). Patients Methods Four-hundred twenty-seven CN-AML were analyzed for mutations by polymerase chain reaction direct sequencing established prognostic gene mutations. Gene- profiles derived using microarrays. Results found 23% patients, older age (P...
To evaluate the prognostic significance of CEBPA mutations in context established molecular markers cytogenetically normal (CN) acute myeloid leukemia (AML) and gain biologic insights into leukemogenesis CN-AML high-risk subset (FLT3 internal tandem duplication [ITD] positive and/or NPM1 wild type) that has a significantly higher incidence than low-risk (FLT3-ITD negative mutated).
Purpose This phase I dose-escalation trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities, and pharmacokinetics of CPX-351. Patients Methods CPX-351 induction administered on days 1, 3, 5 by 90-minute infusion 48 relapsed or refractory patients with acute myeloid leukemia (AML) high-risk myelodysplasia. Doses started at 3 units/m 2 dose doublings in single-patient cohorts until a pharmacodynamic effect (treatment-related adverse events reduction bone marrow...
Purpose To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients primary cytogenetically normal acute myeloid leukemia (CN-AML) gene/microRNA expression signatures. Patients Methods Younger (< 60 years; n = 175) (≥ 225) CN-AML treated intensive cytarabine/anthracycline-based first-line therapy on Cancer Leukemia Group B protocols were centrally analyzed for by polymerase chain reaction direct sequencing established prognostic gene mutations....
Purpose To determine the frequency of DNMT3A mutations, their associations with clinical and molecular characteristics outcome, associated gene- microRNA-expression signatures in primary cytogenetically normal acute myeloid leukemia (CN-AML). Patients Methods Four hundred fifteen previously untreated adults were analyzed for mutations established prognostic gene expression markers. Gene- profiles derived using microarrays. Results Younger (< 60 years; n = 181) older (≥ 234) patients had...
Significance Long noncoding RNAs (lncRNAs) are involved in numerous biological roles including epigenetic regulation, apoptosis, and cell cycle. Whereas lncRNAs contribute to gene metastasis, prognosis solid tumors, their role acute myeloid leukemia (AML) has not been hitherto reported. Here, we show that lncRNA expression profiles associated with recurrent mutations, clinical features, outcome AML. A fraction of these may have a functional leukemogenesis. Furthermore, could be used as...
Abstract Recently, the European LeukemiaNet (ELN) revised its genetic-risk classification of acute myeloid leukemia (AML). We categorized 1637 adults with AML treated cytarabine/anthracycline regimens according to 2022 and 2017 ELN classifications. Compared classification, favorable group decreased from 40% 35% adverse increased 37% 41% patients. The groups seemed accurately reflect treatment outcomes in all patients aged <60 years, but ≥60 relapse rates, disease-free (DFS) overall (OS)...
Abstract Background Acute lymphoblastic leukemia (ALL) in adults is aggressive, with long‐term outcomes impacted by treatment resistance and toxicity. CD52 expressed most cases of B‐ T‐lineage ALL. Alemtuzumab, a humanized immunoglobulin G1 monoclonal antibody that targets CD52, was identified as potential agent to improve efficacy without increasing Methods In this phase 1/2 study (Cancer Leukemia Group B [CALGB] 10102, NCT00061945), course single‐agent alemtuzumab intercalated into CALGB...